New Adjuvant Combo Makes Peptide Cancer Vaccines 10 Times More Potent in Mice | Research

The takeaway

Combining two immune-stimulating molecules (TLR9 + STING agonists) with peptide cancer vaccines produced 10 times stronger anti-tumor T cell responses than the current leading adjuvant, and synergized with checkpoint immunotherapy in mice.

10× stronger response
The K3/c-di-AMP adjuvant induced 10 times higher T cell responses against tumor neopeptides than poly-IC, the leading adjuvant in current clinical trials

What the researchers found

A new adjuvant combination — the TLR9 agonist K3 CpG plus the STING agonist c-di-AMP — produced T cell responses against tumor neopeptides that were 10 times stronger than poly-IC (the leading adjuvant currently in clinical neoantigen vaccine trials). When combined with synthetic long peptides (20-mers) from melanoma and lung mesothelioma neoantigens, this formulation induced potent antigen-specific T cell immunity in mice.

In a melanoma mouse model, the vaccine controlled tumor growth and improved survival, and it synergized with anti-PD-1 checkpoint immunotherapy — meaning the combination worked better than either approach alone.

Why it matters

Neoantigen peptide vaccines are a promising strategy for personalized cancer treatment, but their effectiveness depends heavily on the adjuvant that boosts the immune response. Current clinical trial adjuvants produce modest T cell responses. This study identifies a dramatically more potent adjuvant combination (10× improvement) that also synergizes with checkpoint immunotherapy — the backbone of modern cancer treatment. If this translates to humans, it could significantly improve neoantigen vaccine platforms.

The numbers in context

10× higher T cell responses vs. poly-IC · 20-mer synthetic long peptides · Tested against melanoma and lung mesothelioma neopeptides · Synergy with anti-PD-1 · Tumor growth control and improved survival in B16-F10-OVA mice

How the study worked

Researchers tested the K3 CpG (TLR9 agonist) plus c-di-AMP (STING agonist) adjuvant combination with 20-mer synthetic long peptides in mice. They measured dendritic cell activation, antigen-specific T cell responses against multiple neopeptides (from OVA, melanoma, and mesothelioma), tumor growth, and survival. They compared against poly-IC and tested combination with anti-PD-1 checkpoint therapy.

Who was studied

C57BL/6 mice, including B16-F10-OVA melanoma tumor-bearing mice

What this study cannot tell us

This is entirely a mouse study — the adjuvant combination has not been tested in humans. Mouse immune systems differ from human ones, and tumor models in mice don't fully replicate human cancer complexity. The 10× improvement over poly-IC was measured in mice and may not hold in human clinical settings. Safety and tolerability of the dual-adjuvant combination in humans is unknown.

How to read the evidence

Preliminary evidence from a mouse study. While the 10-fold improvement is striking and the melanoma tumor control data is compelling, no human data exist. The jump from mouse immunology to clinical efficacy in cancer patients is notoriously unpredictable.

When this study was published

Published in 2024 in the Journal of Immunology. Very recent work that contributes to the rapidly evolving neoantigen vaccine field.

The bigger picture

Personalized neoantigen vaccines are one of the most promising frontiers in cancer immunotherapy, with companies like BioNTech and Moderna running clinical trials. The biggest challenge is generating strong enough immune responses. This study suggests that changing the adjuvant — the immune booster paired with the vaccine — could dramatically improve potency. Combined with checkpoint inhibitors, this approach could make peptide cancer vaccines clinically viable for more patients.

Questions still open

Will the 10-fold improvement in T cell responses seen in mice translate to meaningful clinical benefit in human cancer patients?
What is the safety profile of simultaneously activating TLR9 and STING pathways in humans?
Could this adjuvant combination improve neoantigen mRNA vaccines as well as peptide-based ones?

Common questions

What makes this adjuvant combination better than what's currently used?

Current peptide cancer vaccine trials mostly use poly-IC (a TLR3 agonist) as the immune booster. This study's combination of a TLR9 agonist and a STING agonist activates dendritic cells — the immune system's key antigen-presenting cells — much more strongly, resulting in 10 times more cancer-fighting T cells. It also works synergistically with checkpoint immunotherapy drugs.

Could this lead to better cancer vaccines for people?

Potentially. The 10-fold improvement in immune response and the synergy with anti-PD-1 therapy are both promising, but this is mouse data. Human clinical trials would be needed to confirm whether the results translate. Many promising mouse results in cancer immunology have not held up in human patients, so cautious optimism is appropriate.

Read the original research

TLR9 plus STING Agonist Adjuvant Combination Induces Potent Neopeptide T Cell Immunity and Improves Immune Checkpoint Blockade Efficacy in a Tumor Model.

Journal of immunology (Baltimore, Md. : 1950), 212(3), 455-465

View on PubMed ↗Publisher’s paper ↗

Citation

Castro Eiro, Melisa D; Hioki, Kou; Li, Ling; Wilmsen, Merel E P; Kiernan, Caoimhe H; Brouwers-Haspels, Inge; van Meurs, Marjan; Zhao, Manzhi; de Wit, Harm; Grashof, Dwin G B; van de Werken, Harmen J G; Mueller, Yvonne M; Schliehe, Christopher; Temizoz, Burcu; Kobiyama, Kouji; Ishii, Ken J; Katsikis, Peter D. (2024). TLR9 plus STING Agonist Adjuvant Combination Induces Potent Neopeptide T Cell Immunity and Improves Immune Checkpoint Blockade Efficacy in a Tumor Model.. Journal of immunology (Baltimore, Md. : 1950), 212(3), 455-465. https://doi.org/10.4049/jimmunol.2300038